Overview


According to FutureWise analysis the market for antiviral immunoglobulin in 2023 is US$ 4.99 billion, and is expected to reach US$ 9.52 billion by 2031 at a CAGR of 8.4%.

Antiviral immunoglobulin (AVIG) is a specialized immunoglobulin-containing antibody targeting viruses. Immunoglobulins are proteins that are produced by the immune system to combat infections. These antibodies are specific proteins that attach to viruses, impeding their ability to infect cells. AVIG is derived from the blood plasma of individuals who have either been vaccinated against or exposed to particular viruses. The collected plasma undergoes a meticulous process to eliminate potentially harmful cells or bacteria. The resulting antibodies are then concentrated and purified. AVIG finds applications in both the treatment and prevention of various viral infections, including Rabies, Hepatitis B, Tetanus, Varicella-zoster (causing chickenpox and shingles), Measles, Mumps, Rubella, Cytomegalovirus (CMV), Epstein-Barr virus (EBV), and Respiratory syncytial virus (RSV).

Typically administered intravenously, AVIG can be given in a single dose or as a series of doses, depending on the specific infection. Generally, AVIG is considered safe and well-tolerated. However, some individuals may experience side effects like headache, fever, muscle aches, and nausea. Mechanistically, AVIG operates by supplying the body with antibodies targeting specific viruses. These antibodies can bind to the viruses, impeding their ability to infect cells. Additionally, AVIG can aid in neutralizing toxins produced by viruses.

FutureWise Market Research has published a report that provides an insightful analysis of Antiviral Immunoglobulin Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antiviral Immunoglobulin Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  • Sanofi Pasteur SA
  • alecris Biotherapeutics, Inc.
  • Bayer AG
  • AstraZeneca Plc.
  • Biota Holdings Limited
  • Cangene Corporation
  • Omrix Biopharmaceuticals, Inc.
  • CSL Behring
  • Baxter International Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antiviral Immunoglobulin Market:

  • In April 2023, the FDA granted fast-track designation to SAB Biotherapeutics' SAB-176. This designation aims to accelerate the development and review process of SAB-176, a potential treatment for Type A and Type B influenza.

The rising incidence of viral infections, including those caused by hepatitis, rabies, and other viruses, is a significant driver for the antiviral immunoglobulin market. Globally, the population continues to grow, and so does the potential for viral outbreaks, which drives the market. Technological advancements in immunology and biopharmaceuticals have led to the developing of more sophisticated and effective antiviral immunoglobulin therapies. Rising awareness among healthcare professionals and the general public about the availability and benefits of antiviral immunoglobulins is driving market growth. Education campaigns and outreach programs play a vital role in this. Antiviral immunoglobulins are finding new applications beyond traditional uses. They are being explored for emerging viruses and specialized cases, such as immunocompromised patients, propelling the market growth.

Immunoglobulin therapies, including antiviral immunoglobulins, can be expensive. This cost can be a significant barrier, particularly in regions with limited healthcare resources or inadequate insurance coverage. Stringent regulatory requirements for producing and distributing immunoglobulin products can restrain market growth. Ensuring compliance with quality and safety standards is a complex and resource-intensive process. Emerging antiviral medications and treatments, such as antiviral drugs and vaccines, may provide alternative options for some viral infections. These alternatives can compete with antiviral immunoglobulin therapies and constrain market growth.

By Distribution Channels

  • Hospital pharmacies
  • Retail Pharmacies
  • Drug Stores

By Mode of Administration

  • Subcutaneous
  • Intramuscular Injections
  • Intravenous

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to robust healthcare infrastructure, high healthcare expenditure, intense research and development activities, and the prominent presence of key industry players, driving the market expansion and the market. Asia-Pacific region is poised for substantial expansion in the forecast period due to the large population, rising health expenditure, and an escalating demand for high-quality healthcare services.
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Antiviral Immunoglobulin Market By Distribution Channels, By Mode of Administration and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction

    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology

    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antiviral Immunoglobulin Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antiviral Immunoglobulin Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antiviral Immunoglobulin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antiviral Immunoglobulin Market, By Distribution Channels Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Hospital pharmacies
        2. Retail Pharmacies
        3. Drug Stores

  • 8.   Antiviral Immunoglobulin Market, By Mode of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Subcutaneous
        2. Intramuscular Injections
        3. Intravenous

  • 9.   North America Antiviral Immunoglobulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antiviral Immunoglobulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antiviral Immunoglobulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antiviral Immunoglobulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Sanofi Pasteur SA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. alecris Biotherapeutics, Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca Plc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Biota Holdings Limited
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cangene Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Omrix Biopharmaceuticals, Inc.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. CSL Behring
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Baxter International Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11